Сравнение
Mazdutide vs. Semaglutid
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
2259884-03-0
910463-68-2
Молекулярная масса
4790 g/mol
4113.6 g/mol
Период полувыведения
132 h
165 h
Последовательность
synthetisches Oxyntomodulin-Analogon (39 Aminosäuren) mit Fettsäureseitenkettemodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerМеханизм действия
Mazdutide
Mazdutide is a dual agonist at the GLP-1 and glucagon receptors and is structurally derived from the gut hormone oxyntomodulin. The GLP-1 component mediates glucose-dependent insulin secretion, inhibition of glucagon secretion at elevated blood glucose, and modulation of appetite and gastric emptying. The glucagon component can influence energy expenditure and hepatic lipid and glucose metabolism. A fatty-acid side chain enables albumin binding and the weekly administration interval.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
4
4
из них на людях
4
3
Зафиксированные эффекты
4
3
Открытые противоречия
0
1
Задокументированные нежелательные явления
0
5
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between Mazdutide and Semaglutid?
- Mazdutide is classified as "Метаболизм", while Semaglutid is classified as "Метаболизм". Mazdutide: Synthetic oxyntomodulin analogue that simultaneously activates the GLP-1 and glucagon receptors (dual agonist). Developed by Innovent Biologics and Eli Lilly. In China the NMPA approved mazdutide on 27 June 2025 for chronic weight management; a further filing for type 2 diabetes is under review in China. Outside China the substance remains in clinical development. Semaglutid: Long-acting GLP-1 receptor agonist. Approved as a medicinal product for type-2 diabetes (Ozempic, Rybelsus), chronic weight management (Wegovy) and cardiovascular risk in obesity. One of the best-studied substances on this platform — many large human RCTs. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Mazdutide or Semaglutid?
- The highest available evidence level is "РКИ на людях" for Mazdutide and "РКИ на людях" for Semaglutid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Mazdutide and Semaglutid in Germany and the United States?
- Германия: Mazdutide — Только для исследований, Semaglutid — Рецептурный. США: Mazdutide — Только для исследований, Semaglutid — Рецептурный. These are factual summaries with source and review date on the individual pages.